33953-37-6

Basic information

• Product Name: N-PIPERIDIN-4-YL-BENZAMIDE
• Synonyms: 4-BENZIMIDO PIPERIDINE;4-BENZAMIDOPIPERIDINE HYDRATE;4-BENZOYLAMINOPIPERIDINE;BUTTPARK 154\06-76;N-(4-PIPERIDYL)BENZAMIDE;N-(4-PIPERIDYL)BENZAMIDE HYDRATE;N-(4-PIPERIDINYL)BENZAMIDE;N-PIPERIDIN-4-YL-BENZAMIDE
• CAS NO: 33953-37-6
• Molecular Formula: C₁₂H₁₆N₂O
• Molecular Weight: 204.27
• EINECS: 251-759-1
• Product Categories: Amines;Pyrans, Piperidines &Piperazines;Pyrans, Piperidines & Piperazines
• Mol File: 33953-37-6.mol

Chemical Properties

• Melting Point: 137 °C
• Boiling Point: 412.4ºC at 760 mmHg
• Flash Point: 174.8 ºC
• Appearance: /
• Density: 1.11 g/cm³
• Vapor Pressure: 5.26E-06mmHg at 25°C
• Refractive Index: 1.558
• Storage Temp.: 2-8°C
• PKA: 14.35±0.20(Predicted)
• CAS DataBase Reference: N-PIPERIDIN-4-YL-BENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-PIPERIDIN-4-YL-BENZAMIDE(33953-37-6)
• EPA Substance Registry System: N-PIPERIDIN-4-YL-BENZAMIDE(33953-37-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 33953-37-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-PIPERIDIN-4-YL-BENZAMIDE is used as a precursor in the preparation of [(azaheterocyclyl)thiazolyl] heteroaryl ketones, which are vanin-1 inhibitors. These inhibitors play a crucial role in the development of drugs targeting various diseases, including cancer and inflammatory conditions, by modulating the activity of vanin-1 enzymes.

InChI:InChI=1/C12H16N2O/c13-12(15)11-3-1-9(2-4-11)10-5-7-14-8-6-10/h1-4,10,14H,5-8H2,(H2,13,15)

Upstream product

• 971-34-6 1-benzyl-4-benzamidopiperidine 
• 955050-02-9 tert-butyl 4-benzamidopiperidine-1-carboxylate 
• 13035-19-3 4-aminopiperidine 
• 10364-94-0 1-benzoylimidazole 
• 35621-01-3 4-aminopiperidine dihydrochloride 
• 65-85-0 benzoic acid 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 50541-93-0 4-amino-1-benzylpiperidine 
• 98-88-4 benzoyl chloride 
• 4783-65-7 N-benzyl-2-piperidinone 

Downstream Products

• 36793-55-2 2-[2-(4-benzoylamino-piperidin-1-yl)-acetylamino]-4-phenyl-thiazole-5-carboxylic acid ethyl ester 
• 36806-84-5 N-(1-{2-[4-(4-chloro-phenyl)-2-phenyl-thiazol-5-yl]-ethyl}-piperidin-4-yl)-benzamide 
• 577778-27-9 1-Acetyl-4-benzamidopiperidin 
• 387825-73-2 2-[2-(4-benzamino-1-piperidyl)ethyl]-1,2,3,4-tetrahydro-1-oxo-naphthalene 
• 57368-81-7 1-(3-benzoylpropyl)-4-benzamidopiperidine 
• 36793-39-2 1-Phenacyl-4-benzamidopiperidine 
• 52818-58-3 4-benzamido-1-(2-hydroxyethyl)piperidine 
• 36793-41-6 N-[1-(2-naphthalen-1-yl-ethyl)-piperidin-4-yl]-benzamide 
• 36807-02-0 N-(1-benzo[1,3]dioxol-5-ylmethyl-piperidin-4-yl)-benzamide 
• 36793-45-0 N-[1-(2-pyridin-4-yl-ethyl)-piperidin-4-yl]-benzamide 
• 57467-19-3 N-[1-(2-pyridin-2-yl-ethyl)-piperidin-4-yl]-benzamide 
• 730234-12-5 4-benzamido-1-(2-diethylaminoethyl)piperidine 

Relevant articles and documents

Synthesis and structure–activity relationship of N-(piperidin-4-yl)benzamide derivatives as activators of hypoxia-inducible factor 1 pathways

Guided by bioisosterism and pharmacokinetic parameters, we designed and synthesized a series of novel benzamide derivatives. Preliminary in vitro studies indicated that compounds 10b and 10j show significant inhibitory bioactivity in HepG2 cells (IC50 values of 0.12 and 0.13?μM, respectively). Compounds 10b and 10j induced the expression of HIF-1α protein and downstream target gene p21, and upregulated the expression of cleaved caspase-3 to promote tumor cells apoptosis.

CDI-mediated monoacylation of symmetrical diamines and selective acylation of primary amines of unsymmetrical diamines

A highly efficient and green protocol for monoacylation of symmetrical diamines and chemoselective acylation of primary amines of unsymmetrical diamines has been developed.

Discovery of N-{1-[3-(3-Oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl] piperidin-4-yl}-2-phenylacetamide (Lu AE51090): An allosteric muscarinic M 1 receptor agonist with unprecedented selectivity and procognitive potential

The discovery and Structure-activity relationship (SAR) of a series of allosteric muscarinic M1 receptor agonists are described. Compound 17 (Lu AE51090) was identified as a representative compound from the series, based on its high selectivity as an agonist at the muscarinic M1 receptor across a panel of muscarinic receptor subtypes. Furthermore, 17 displayed a high degree of selectivity when tested in a broad panel of G-protein-coupled receptors, ion channels, transporters, and enzymes, and 17 showed an acceptable pharmacokinetic profile and sufficient brain exposure in rodents in order to characterize the compound in vivo. Hence, in a rodent model of learning and memory, 17 reversed delay-induced natural forgetting, suggesting a procognitive potential of 17.

4-Aminopiperidine derivatives as a new class of potent cognition enhancing drugs

Extrusion of one of the nitrogens of the piperazine ring of potent nootropic drugs previously described gave 4-aminopiperidine analogues that maintained high cognition enhancing activity in the mouse passive avoidance test. One of the new compounds (9, active at 0.01 mg/kg ip) may represent a new lead for the development of cognition enhancers useful to treat the cognitive deficit produced by neurodegenerative pathologies like Alzheimer's disease.

5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines

This invention is directed to dihydropyrimidine compounds of the following formula: which are selective antagonists for human α1Areceptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where antagonism of the α1Areceptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Use of oxido-squalene cyclase inhibitors to lower blood cholesterol

PCT No. PCT/GB96/01985 Sec. 371 Date Feb. 13, 1998 Sec. 102(e) Date Feb. 13, 1998 PCT Filed Aug. 14, 1996 PCT Pub. No. WO97/06802 PCT Pub. Date Feb. 27, 1997A compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein G, T1, T2 and T3 are selected from CH and N; provided that T2 and T3 are not both CH; A is selected from a direct bond and (1-4C)alkylene; X is selected from oxy, thio, sulphinyl, sulphonyl, carbonyl, carbonylamino, N-di-(1-6C)alkylcarbonylamino, sulphonamido, methylene, (1-4C)alkylmethylene and di-(1-6C)alkylmethylene, and when T2 is CH, X may also be selected from aminosulphonyl and oxycarbonyl; and Q is selected from (5-7C)cycloalkyl, a heterocyclic moiety containing up to 4 heteroatoms selected from nitrogen, oxygen and sulphur, phenyl, naphthyl, phenyl(1-4C)alkyl and phenyl(2-6C)alkenyl; for the manufacture of a medicament for treating diseases or medical conditions in which an inhibition of oxido-squalene cyclase is desirable.